Merck & Co. and Calla Lily Clinical Care announced a partnership to develop Callavid, a leak‑resistant intravaginal drug delivery device. The collaboration builds on Calla Lily’s patented technology and Merck’s global research and commercial capabilities.
Callavid is a small, tampon‑shaped device that incorporates an absorbent liner, allowing it to stay in place while medication is absorbed and then be removed cleanly. The platform targets fertility and pregnancy support, oncology, menopause, infectious diseases, and live biotherapeutics aimed at reducing antibiotic use.
For Merck, the deal expands its women’s health portfolio and introduces a differentiated delivery modality that could extend the lifecycle of existing and future vaginal therapeutics. The partnership aligns with Merck’s strategy to diversify beyond its oncology core and capitalize on growth opportunities in women’s health.
Calla Lily gains access to Merck’s scientific heritage and commercial infrastructure, positioning Callavid for accelerated clinical development and potential market entry. The collaboration marks Calla Lily’s first industry partnership and provides the resources needed to move the platform from pre‑clinical to clinical stages.
Merck’s Q4 2025 results showed worldwide sales of $16.4 billion, up 5% YoY, and GAAP diluted EPS of $1.19, a beat of $0.24 against consensus of $0.95. The earnings beat was driven by strong performance of Keytruda and new launches such as Winrevair, offsetting a decline in the vaccine franchise. However, Merck’s 2026 guidance capped worldwide sales at $65.5 billion to $67.0 billion and adjusted EPS at $5.00 to $5.15, below analysts’ expectations of $5.63 and $67.58 billion. The lower guidance reflects a one‑time charge of approximately $3.65 per share related to the acquisition of Cidara and a cautious outlook on future growth.
Investors reacted to the guidance, focusing on the conservative outlook and the impact of the Cidara charge. Management emphasized continued confidence in its portfolio, with Chairman and CEO Rob Davis noting that the company remains “well positioned to deliver on its purpose for patients and create durable value for shareholders” while navigating a competitive landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.